Large-Scale Presentation of New Fexuclue Data at DDW 2025
Daewoong Pharmaceutical Showcases Latest Research and Clinical Excellence to Global Medical Community
On the 4th of this month (local time) at the DDW 'Night of Pecsucle' symposium held in San Diego, USA, Professor Michael Baeji (from the left in the photo), Professor Jose Maria Lemes Troche, Professor Arnold Rikelme, and Professor Dohoon Kim are engaged in discussion. Photo by Daewoong Pharmaceutical
Daewoong Pharmaceutical presented the latest research data and the excellence of its gastroesophageal reflux disease treatment, Fexuclue, to medical professionals worldwide at the world’s largest academic event.
On May 20, Daewoong Pharmaceutical announced that it had successfully operated an academic booth for Fexuclue and held the 'Fexuclue Reception Night' symposium at Digestive Disease Week 2025 (DDW), the world’s largest academic event in the field of gastroenterology.
DDW, held from May 3 to May 6 in San Diego, USA, is the world’s largest international congress on gastroenterology, attended annually by physicians, researchers, and industry professionals from around the globe. At Daewoong Pharmaceutical’s academic booth and symposium, the latest insights and key research achievements related to Fexuclue were highlighted.
At the Fexuclue booth, Daewoong Pharmaceutical introduced the drug’s unique strengths to medical professionals worldwide, including its rapid onset of action, fast and superior improvement of symptoms both day and night, and high convenience with once-daily dosing regardless of meals.
Notably, during DDW 2025, Daewoong Pharmaceutical unveiled a total of five new data sets related to Fexuclue, the largest number of research results disclosed among domestic P-CAB class treatments. The new studies presented included: ▲ research demonstrating the preventive effect against NSAIDs-induced peptic ulcers, ▲ a phase 3 study on the treatment of erosive esophagitis (EE) in Indian patients, ▲ a study on low-risk mechanisms related to Alzheimer’s disease, ▲ an evaluation of improvement in nocturnal gastric acid secretion symptoms, and ▲ research on anti-inflammatory and antioxidant effects in a Helicobacter pylori (H. pylori)-induced gastritis model.
The 'Fexuclue Reception Night' symposium, held on May 4, was attended by approximately 100 medical professionals from Korea and abroad. Speakers included Dr. Michael Baeji, Professor of Gastroenterology at Vanderbilt University Medical Center in the United States; Professor Dohoon Kim, Professor of Gastroenterology at Asan Medical Center in Seoul; Professor Arnold Rikelme, Professor of Gastroenterology at Pontifical Catholic University of Chile; and Professor Jose Maria Lemes Troche, Director of the Institute of Biomedical Sciences at Universidad Veracruzana in Mexico.
In the first session, Dr. Michael Baeji, Professor of Gastroenterology at Vanderbilt University Medical Center, stated, “(For gastroesophageal reflux disease) PPIs are associated with delayed onset of action, insufficient acid suppression, failure to control nocturnal acid secretion, inconvenience of dosing before meals, and various side effects with long-term use.” He added, “P-CABs have emerged as drugs that can overcome the limitations of PPIs, and among them, Fexuclue, which was developed relatively recently, can serve as a new treatment option for gastroesophageal reflux disease.”
Professor Dohoon Kim of Asan Medical Center highlighted the molecular structural uniqueness of Fexuclue, emphasizing its long half-life and rapid, potent symptom suppression. He explained, “Fexuclue can quickly improve and alleviate gastroesophageal reflux disease symptoms, thereby enhancing quality of life.”
Fexuclue was also introduced as an effective alternative for H. pylori eradication therapy, which is considered a cause of gastric ulcers and gastric cancer. Professor Arnold Rikelme of Pontifical Catholic University of Chile, who spoke during this session, presented interim results from a study on Fexuclue-based quadruple therapy for H. pylori eradication in Latin American patients. He reported an eradication rate of 96%, suggesting the potential for expansion as a practical treatment option.
The Fexuclue quadruple therapy is a combination regimen for treating H. pylori infection, consisting of Fexuclue, the antibiotics amoxicillin and metronidazole, and a bismuth preparation. Compared to conventional PPI-based therapy, this regimen more reliably establishes an environment for eradication through stronger and more sustained gastric acid suppression.
Subsequently, Professor Jose Maria Lemes Troche, Director of the Institute of Biomedical Sciences at Universidad Veracruzana in Mexico, presented a clinical study demonstrating the superior gastric acid suppression effect of Fexuclue in healthy Mexican subjects. He noted that Fexuclue is characterized by a long half-life and improvement in major symptoms such as heartburn, reflux, and dyspepsia, as well as patient quality of life. He particularly emphasized that Fexuclue is effective even when taken on-demand, rather than continuously, making it a suitable treatment for patients with non-erosive reflux disease (NERD).
Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, “Through DDW 2025, we were able to effectively introduce Fexuclue’s three major strengths?‘rapid and excellent symptom relief (Reliever),’ ‘sustained acid suppression through a long half-life (Controller),’ and ‘broad therapeutic effects for various gastroesophageal reflux disease symptoms (All-Rounder)’?to medical professionals worldwide. We will continue our efforts to ensure that Fexuclue is established as an effective treatment option for gastroesophageal reflux disease in clinical settings globally.”
Meanwhile, Fexuclue was launched last month in India, the world’s fourth-largest anti-ulcer drug market, as the first domestically developed P-CAB, and subsequently received product approval in Panama, accelerating its overseas expansion. Currently, Fexuclue has entered a total of 30 countries and is being sold in six countries, including Korea.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
